Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.027
Sell
RSI(14)
39.504
Neutral
STOCH(KDJ)(9,3,3)
39.935
Buy
ATR(14)
0.164
High Vlolatility
CCI(14)
-37.079
Neutral
Williams %R
66.667
Sell
TRIX(12,20)
-1.200
Sell
StochRSI(14)
100.000
Buy
ABVC Biopharma Inc
ABVC2.190USD
+0.150+7.35%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
52.98MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ABVC Biopharma Inc
Currency: USD Updated: 2025-12-19Key Insights
ABVC Biopharma Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 208/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ABVC Biopharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ABVC Biopharma Inc Highlights
StrengthsRisks
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing products and technologies to combat various diseases. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV- 1501, ABV-1519 and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine to treat Major Depressive Disorder (MDD). ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer. It also focuses on the development of new drugs and medical devices derived from plants.
Growing
The company is in a growing phase, with the latest annual income totaling USD 509.59K.
Undervalued
The company’s latest PE is -7.81, at a low 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 110.50K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of ABVC Biopharma Inc is 7.88, ranking 74/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 795.95K, representing a year-over-year increase of 104.47%, while its net profit experienced a year-over-year increase of 568.15%.
Score
Financials
5.25
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.02
Operational Efficiency
10.00
Growth Potential
9.61
Shareholder Returns
7.52
ABVC Biopharma Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of ABVC Biopharma Inc is 6.89, ranking 212/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.81, which is -97.09% below the recent high of -0.23 and -138.00% above the recent low of -18.59.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 208/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19No earnings forecast score is currently available for ABVC Biopharma Inc. The Biotechnology & Medical Research industry's average is 8.02.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of ABVC Biopharma Inc is 6.44, ranking 253/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.72 and the support level at 1.81, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.070
Buy
MA10
2.129
Buy
MA20
2.357
Sell
MA50
2.675
Sell
MA100
2.806
Sell
MA200
2.243
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of ABVC Biopharma Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 3.34%, representing a quarter-over-quarter decrease of 3.13%. The largest institutional shareholder is The Vanguard, holding a total of 267.45K shares, representing 1.10% of shares outstanding, with 204.20% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Jiang (Shuling)
YuanGene, Corp
Jiang (Tsung-Shann)
Geode Capital Management, L.L.C.
Jiang (Eugene)
State Street Investment Management (US)
Patil (Uttam)
Odaira (Yoshinobu)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of ABVC Biopharma Inc is 3.09, ranking 175/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.25. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.25
VaR
+12.50%
240-Day Maximum Drawdown
+57.17%
240-Day Volatility
+124.14%
Return
Best Daily Return
60 days
+7.35%
120 days
+28.30%
5 years
+137.08%
Worst Daily Return
60 days
-12.03%
120 days
-28.42%
5 years
-50.00%
Sharpe Ratio
60 days
-2.52
120 days
+0.53
5 years
+0.49
Risk Assessment
Maximum Drawdown
240 days
+57.17%
3 years
+95.45%
5 years
--
Return-to-Drawdown Ratio
240 days
+3.87
3 years
-0.24
5 years
--
Skewness
240 days
+2.84
3 years
+2.58
5 years
+3.49
Volatility
Realised Volatility
240 days
+124.14%
5 years
--
Standardised True Range
240 days
+8.57%
5 years
--
Downside Risk-Adjusted Return
120 days
+77.99%
240 days
+77.99%
Maximum Daily Upside Volatility
60 days
+42.54%
Maximum Daily Downside Volatility
60 days
+45.91%
Liquidity
Average Turnover Rate
60 days
+2.54%
120 days
+2.58%
5 years
--
Turnover Deviation
20 days
-93.96%
60 days
-84.99%
120 days
-84.72%
Peer Comparison
Biotechnology & Medical Research
ABVC Biopharma Inc
ABVC
4.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of ABVC Biopharma Inc?
The TradingKey Stock Score provides a comprehensive assessment of ABVC Biopharma Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of ABVC Biopharma Inc’s performance and outlook.
How do we generate the financial health score of ABVC Biopharma Inc?
To generate the financial health score of ABVC Biopharma Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects ABVC Biopharma Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of ABVC Biopharma Inc.
How do we generate the company valuation score of ABVC Biopharma Inc?
To generate the company valuation score of ABVC Biopharma Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare ABVC Biopharma Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of ABVC Biopharma Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of ABVC Biopharma Inc.
How do we generate the earnings forecast score of ABVC Biopharma Inc?
To calculate the earnings forecast score of ABVC Biopharma Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on ABVC Biopharma Inc’s future.
How do we generate the price momentum score of ABVC Biopharma Inc?
When generating the price momentum score for ABVC Biopharma Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of ABVC Biopharma Inc’s prices. A higher score indicates a more stable short-term price trend for ABVC Biopharma Inc.
How do we generate the institutional confidence score of ABVC Biopharma Inc?
To generate the institutional confidence score of ABVC Biopharma Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about ABVC Biopharma Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of ABVC Biopharma Inc.
How do we generate the risk management score of ABVC Biopharma Inc?
To assess the risk management score of ABVC Biopharma Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of ABVC Biopharma Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of ABVC Biopharma Inc.
